TMS and psilocybin-assisted therapy are two of the most talked-about alternatives to traditional antidepressants right now. One major difference: TMS is FDA-approved and widely available. Psilocybin therapy is still in clinical trials (as of 2026) and not yet FDA-approved for depression.
What You’ll Learn
- How the mechanisms differ
- Availability differences (FDA-approved vs experimental)
- Efficacy comparison
- Treatment experience differences
- Safety considerations
How They Work
TMS: Magnetic pulses target the left DLPFC to restore activity in mood-regulating brain circuits. Treatment builds over 6-9 weeks. No altered states of consciousness. You’re fully yourself the entire time.
Psilocybin therapy: A psychedelic compound that binds to serotonin 2A receptors, temporarily disrupting the default mode network (DMN). This opens a window of enhanced neuroplasticity and psychological insight, paired with therapeutic support before, during, and after sessions.
Efficacy
| Outcome | TMS | Psilocybin (clinical trials) |
|---|---|---|
| Response rate | 50-60% | 60-80% (in controlled settings) |
| Remission rate | 30-35% | 40-55% (COMPASS and Hopkins trials) |
| Sessions needed | 36 over 6-9 weeks | 1-2 dosing sessions (+ prep/integration) |
| Duration of effect | 6-12 months | Highly variable (weeks to years) |
Those psilocybin numbers are impressive. But a caveat: they come from carefully controlled settings with extensive psychological support. Real-world results may look different.
The Experience
TMS: Sit in a chair, tapping sensation on your forehead, 19-37 minutes. No altered consciousness. Drive yourself home. Repeat daily for 6-9 weeks.
Psilocybin: 1-2 supervised sessions lasting 6-8 hours each. Profound altered states — visual distortion, deep emotional processing, ego dissolution, mystical experiences. Trained therapists stay with you the whole time. You’ll do preparation sessions before and integration sessions after.
Availability (as of 2026)
TMS: FDA-approved. Available at 1,000+ clinics across the US. Covered by most insurance after medication failures.
Psilocybin: Not FDA-approved (breakthrough therapy designation granted). Available only through clinical trials at research institutions, Oregon’s regulated psilocybin services (Measure 109), and a growing number of state-level programs. Not covered by insurance.
Safety
TMS: Minimal risks. Scalp discomfort, mild headache. Seizure risk under 0.01%. No psychological risks.
Psilocybin: Physically safe in supervised settings. The psychological risks are real though — challenging experiences (“bad trips”), anxiety, paranoia, and the potential to trigger latent psychosis in vulnerable people. Contraindicated if you have a psychotic disorder or family history of schizophrenia.
Most people would start with the FDA-approved, widely available option (TMS) first and consider psilocybin through trials or state programs if TMS doesn’t work.
Search for TMS providers or explore other device comparisons.
Key Takeaways
- TMS is FDA-approved and widely available; psilocybin is experimental
- TMS is covered by insurance; psilocybin therapy is not
- Psilocybin produces profound altered states; TMS requires no mindset change
- TMS has 15+ years of post-approval clinical data
- Start with TMS — psilocybin is accessible through trials and state programs
Find a TMS Clinic
Browse verified TMS providers, compare clinics, and find the right treatment for your situation.